|
C16ORF88 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
1.11630005239505E-09 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
8.5007556549499E-12 |
| Stage1-vs-Stage2 |
1.610820E-01 |
| Stage1-vs-Stage3 |
6.565200E-01 |
| Stage1-vs-Stage4 |
6.042200E-01 |
| Stage2-vs-Stage3 |
2.875000E-01 |
| Stage2-vs-Stage4 |
1.608230E-01 |
| Stage3-vs-Stage4 |
4.693400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.34190003553414E-09 |
| Normal-vs-Asian |
1.64135371960583E-12 |
| Caucasian-vs-AfricanAmerican |
2.036600E-01 |
| Caucasian-vs-Asian |
9.098900E-03 |
| AfricanAmerican-vs-Asian |
3.536300E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
9.554400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
<1E-12 |
| Normal-vs-Age(81-100Yrs) |
2.39109999999876E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.723400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.161000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.865800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.682800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.152600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.830400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.370600E-01 |
| Classical-VS-Follicular |
2.66140000038106E-07 |
| Classical-VS-Other |
1.942010E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
3.66760000000133E-05 |
| Tall-VS-Other |
3.944100E-02 |
| Tall-VS-Normal |
7.43849426498855E-15 |
| Follicular-VS-Other |
6.986800E-01 |
| Follicular-VS-Normal |
3.52810003434456E-10 |
| Other-VS-Normal |
9.74360000000063E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.17979967409576E-10 |
| N0-vs-N1 |
4.192000E-01 |
|
|
